An engineered transforming growth factor β (TGF-β) monomer that functions as a dominant negative to block TGF-β signaling.
Ontology highlight
ABSTRACT: The transforming growth factor β isoforms, TGF-β1, -β2, and -β3, are small secreted homodimeric signaling proteins with essential roles in regulating the adaptive immune system and maintaining the extracellular matrix. However, dysregulation of the TGF-β pathway is responsible for promoting the progression of several human diseases, including cancer and fibrosis. Despite the known importance of TGF-βs in promoting disease progression, no inhibitors have been approved for use in humans. Herein, we describe an engineered TGF-β monomer, lacking the heel helix, a structural motif essential for binding the TGF-β type I receptor (TβRI) but dispensable for binding the other receptor required for TGF-β signaling, the TGF-β type II receptor (TβRII), as an alternative therapeutic modality for blocki
SUBMITTER: Kim SK
PROVIDER: S-EPMC5409485 | biostudies-literature | 2017 Apr
REPOSITORIES: biostudies-literature
ACCESS DATA